OTCMKTS:CYDY

CytoDyn - CYDY Stock Forecast, Price & News

$0.34

-0.03 (-8.09%)

(As of 03/20/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.33
▼
$0.38
50-Day Range: $0.24
▼
$0.42
52-Week Range: $0.15
▼
$1.26

Volume: 1.41 million shs
Average Volume: 1.94 million shs
Market Capitalization: $285.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

Headlines

SEC Filings

Short Interest

About CytoDyn (OTCMKTS:CYDY) Stock

CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

Receive CYDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter.

CYDY Stock News Headlines

February 27, 2023 | forbes.com

A Court Case With High Implications For The Tech Sector And Inflation Still Higher Than Expected - Forbes AI Newsletter February 25th

January 15, 2023 | nz.finance.yahoo.com

CytoDyn Inc. (CYDY) stock historical prices & data – Yahoo Finance

March 21, 2023 | PressReach (Ad)

Stocks Positioned For The Year

This breakthrough stock has bright future this decade.

December 31, 2022 | seekingalpha.com

CytoDyn: There Seems To Be No Redemption

December 23, 2022 | finance.yahoo.com

CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO

November 22, 2022 | finance.yahoo.com

CytoDyn to Host R&D Update on Wednesday, December 7, 2022

October 20, 2022 | finance.yahoo.com

CytoDyn Announces Appointment of Additional Directors with Industry Experience

October 20, 2022 | globenewswire.com

CytoDyn Announces Appointment of Additional Directors with Industry Experience - GlobeNewswire

March 21, 2023 | PressReach (Ad)

Stocks Positioned For The Year

This breakthrough stock has bright future this decade.

October 13, 2022 | streetinsider.com

Form 10-Q/A CytoDyn Inc. For: Aug 31 - StreetInsider.com

September 8, 2022 | finance.yahoo.com

CytoDyn Inc. (CYDY)

August 24, 2022 | globenewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY - GlobeNewswire

August 24, 2022 | seekingalpha.com

CytoDyn: It Only Takes One Hit (OTCMKTS:CYDY) - Seeking Alpha

August 9, 2022 | benzinga.com

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of CytoDyn Inc. (CYDY) Investigation - Benzinga

July 14, 2022 | bizjournals.com

5 things to know: Celebrating Genny Nelson's life - Portland Business Journal - The Business Journals

July 13, 2022 | globenewswire.com

CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President - GlobeNewswire

July 13, 2022 | finance.yahoo.com

CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President

June 22, 2022 | globenewswire.com

CytoDyn to Hold Webcast to Provide a Quarterly Company Update - GlobeNewswire

June 13, 2022 | seekingalpha.com

CytoDyn Stock: Nearly Impossible To Revive This Company - Seeking Alpha

May 23, 2022 | finance.yahoo.com

CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer - Yahoo Finance

May 23, 2022 | finance.yahoo.com

CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer

May 13, 2022 | finance.yahoo.com

CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor

April 12, 2022 | benzinga.com

CytoDyn Announces Publication of Peer-Reviewed Paper, "Suppression of Human and Simian Immunodeficie - Benzinga

April 12, 2022 | globenewswire.com

CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species” - GlobeNewswire

April 12, 2022 | finance.yahoo.com

CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”

April 12, 2022 | bizjournals.com

Appeals court rules in favor of former CytoDyn CEO Nader Pourhassan in stock case - Portland Business Journal - The Business Journals

April 7, 2022 | finance.yahoo.com

Global Vasculitis Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight - Yahoo Finance

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CYDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter.

CYDY Company Calendar

Last Earnings: 1/09/2023
Today: 3/21/2023
Fiscal Year End: 5/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:CYDY
Previous Symbol: NASDAQ:CYDY
CUSIP: 23283M101
CIK: 1175680
Web: www.cytodyn.com
Phone: (360) 980-8524
Fax: N/A
Employees: 24
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-210,820,000.00
Net Margins: N/A
Pretax Margin: -82,877.34%
Return on Equity: N/A
Return on Assets: -435.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.05
Quick Ratio: 0.05

Sales & Book Value

Annual Sales: $270,000.00
Price / Sales: 1,057.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.13) per share
Price / Book: -2.62

Miscellaneous

Outstanding Shares: 838,120,000
Free Float: 828,898,000
Market Cap: $285.46 million
Optionable: Not Optionable
Beta: 0.27

Key Executives

Cyrus Arman
President

Antonio Migliarese
CFO, Secretary, Treasurer & CAO

Christopher P. Recknor
Senior Director-Research & Development

Michael D. Mulholland
Senior Vice President-Finance

Cristina de Leon
Head-Investor Relations

Key Competitors

View All Competitors

CYDY Stock - Frequently Asked Questions

How have CYDY shares performed in 2023?: CytoDyn's stock was trading at $0.2250 on January 1st, 2023. Since then, CYDY stock has increased by 51.4% and is now trading at $0.3406.
View the best growth stocks for 2023 here.
How were CytoDyn's earnings last quarter?: CytoDyn Inc. (OTCMKTS:CYDY) announced its earnings results on Monday, January, 9th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter.
What other stocks do shareholders of CytoDyn own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), NVIDIA (NVDA), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Vaxart (VXRT), Nokia Oyj (NOK), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Moderna (MRNA).
What is CytoDyn's stock symbol?: CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

How do I buy shares of CytoDyn?: Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is CytoDyn's stock price today?: One share of CYDY stock can currently be purchased for approximately $0.34.
How much money does CytoDyn make?: CytoDyn (OTCMKTS:CYDY) has a market capitalization of $285.46 million and generates $270,000.00 in revenue each year.
How can I contact CytoDyn?: CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The official website for the company is www.cytodyn.com. The biotechnology company can be reached via phone at (360) 980-8524 or via email at mciszewski@cytodyn.com.

This page (OTCMKTS:CYDY) was last updated on 3/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial